Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Journal of Business News.
Guggenheim Securities Hires Joel Fishbein to Expand Technology Investment Banking Practice
GlobeNewswire, Inc.
·
August 7, 2025
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Joel Fishbein will join the firm’s Technology investment banking practice as a...
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire, Inc.
·
August 7, 2025
Soquelitinib data from cohort 3 of atopic dermatitis Phase 1 clinical trial demonstrates earlier and deeper responses compared to cohorts 1-2 along with clinically meaningful reduction in itch as early as day 8 Enrollment ongoing in Phase 1 trial...
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire, Inc.
·
August 7, 2025
- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) - - CX-2051 Phase 1 dose expansions on track for data update in Q1 2026....
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
GlobeNewswire, Inc.
·
August 7, 2025
Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) top-line results anticipated in September 2025; the first of three catalysts for the claseprubart neuromuscular franchise by YE’26 Phase 3 CAPTIVATE trial of...
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025
GlobeNewswire, Inc.
·
August 7, 2025
$60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reiterated SAN CARLOS, Calif., Aug. 07, 2025 (GLOBE...
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire, Inc.
·
August 7, 2025
Phase 2b NAVIGATE clinical trial evaluating CD388 for the prevention of seasonal influenza met primary and all secondary efficacy endpoints for all dose groups End of Phase 2 meeting request submitted to the U.S. Food and Drug Administration (FDA)...
Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire, Inc.
·
August 7, 2025
Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV Four Scientific Posters Presented at EASL, Including Final Results from Phase 2 Study of Bemnifosbuvir/Ruzasvir Regimen Confirming 98% Sustained Virologic Response at 12...
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire, Inc.
·
August 7, 2025
Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3 ReDiscover-2 trial in Q2 Approximately $657...
89bio Reports Second Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire, Inc.
·
August 7, 2025
– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 topline histology data expected in 1H 2027 and in 2028, respectively; each trial designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis...
Deadline Alert: Reddit, Inc. (RDDT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
GlobeNewswire, Inc.
·
August 7, 2025
LOS ANGELES, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 18, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise...
Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update
GlobeNewswire, Inc.
·
August 7, 2025
Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025 Patient enrollment in Skye’s CBeyondTM Phase 2a obesity trial extension study initiated Independent Data Safety Monitoring Committee completed...
Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire, Inc.
·
August 7, 2025
Regulatory Reviews of Aficamten for Obstructive HCM Progressing in U.S., E.U. and China; Late-Cycle Meeting with U.S. FDA Scheduled for September Ahead of December 26, 2025 PDUFA Date Primary Results from MAPLE-HCM to be Presented in a Hot Line...
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire, Inc.
·
August 7, 2025
BEACON-IPF close out activities continue Previously announced workforce and operational realignment largely complete Phase 1 oncology trial on track to deliver additional data by the end of the year SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025...
Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update
GlobeNewswire, Inc.
·
August 7, 2025
– Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data demonstrating bioequivalence of novel, bispecific GLP-1/GLP-2 receptor agonist delivered orally via RaniPill (RT-114) compared to...
Interpace Biosciences Announces Second Quarter 2025 Financial and Business Results
GlobeNewswire, Inc.
·
August 7, 2025
● Q2 Revenue of $9.2 million ● Q2 Cash Collections of $10.8 million ● Q2 Thyroid test volume up 16% year-over-year to record levels ● Q2 Thyroid revenue of $8.7M; up 25% year-over-year to record levels PARSIPPANY, NJ, Aug. 07, 2025 (GLOBE...
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire, Inc.
·
August 7, 2025
Announced strategic partnership with Simcere Zaiming for Phase 1 program SIM0505 (CDH6 ADC) with plans to dose the first SIM0505 patient in the United States this quarter Currently in cohort 4 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple...
Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress
GlobeNewswire, Inc.
·
August 7, 2025
Positive topline Phase 2a biomarker data position VTX3232 as a potential disease-modifying therapy for patients with Parkinson’s disease Data from the Phase 2 study of VTX2735 in patients with recurrent pericarditis expected in Q4 2025 Phase 2...
scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire, Inc.
·
August 7, 2025
Generated net FUROSCIX® revenue of $16 million in the second quarter of 2025; up 99% over Q2 2024 Doses shipped to patients increased 45% over Q1 2025 and 117% over Q2 2024 Launch of FUROSCIX in chronic kidney disease Autoinjector remains on track...
Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire, Inc.
·
August 7, 2025
Strong execution and continued progress across pipeline Unprecedented data delivered from Phase 2 CSU study demonstrating profound, sustained complete response and improved quality of life 7 months after completion of barzolvolimab dosing Data...
Regeneron Announces Investor Conference Presentations
GlobeNewswire, Inc.
·
August 7, 2025
TARRYTOWN, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Cantor Global Healthcare Conference 2025 at 1:35 p.m. ET on Wednesday, September 3, 2025 2025 Wells...